Consistently, treatment with a STAT3 inhibitor, Stattic, in NKYS and SNK6 reduced pSTAT3 and PD-L1 expression levels (Figure 4D-F), which was also observed in p.E616K-expressing Ba/F3 cells (supplemental Figure 5). activated STAT3 to the PD-L1 gene promoter. Consistent with these findings, PD-L1 was overexpressed in NKTL cell lines harboring hotspot mutations, and similar findings were observed by the overexpression of p.E616K and p.E616G in the wild-type NKTL cell line. Conversely, STAT3 silencing and inhibition decreased PD-L1 expression in mutant NKTL cell lines. In NKTL tumors, STAT3 activation correlated significantly with PD-L1 expression. We demonstrated that STAT3 activation confers high PD-L1 expression, which may promote tumor immune evasion. The combination of PD-1/PD-L1 antibodies and STAT3 inhibitors might be a promising therapeutic approach for NKTL, and possibly PTCL. Visual Abstract Open in a separate window Introduction Mature T-cell MG-262 lymphomas, including peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTL), appear to have a geographical predilection for Asia.1-3 The World Health Organization classification recognizes a number of distinctive subtypes of PTCL and NKTL, including angioimmunoblastic T-cell lymphoma, anaplastic MG-262 lymphoma kinase-positive (ALK+) and anaplastic lymphoma kinase-negative (ALK?) anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), and PTCL not otherwise specified (PTCL-NOS).4 With the exception of ALK+ ALCL, patients with PTCL and NKTL generally have a poor prognosis, with 5-year overall survival rates less than 40%.4 Multiple studies have suggested that the JAK/STAT pathway plays a significant role in the pathogenesis of PTCL and NKTL. We previously identified activating mutations in about one-third of NKTL cases.5 Activating mutations of and/or were found in 18% of ALK? ALCL, while being absent either in ALK+ ALCL or in PTCL-NOS.6 In contrast, and mutations were recently reported in 2 of 4 patients with PTCL-NOS.7 Collectively, the mutation frequencies varied greatly among the PTCL and NKTL subtypes and between studies. In NKTL, was constitutively activated in 87% of cases; however, only 21% of these could be explained by mutations. This suggests the presence of key activating and/or cooperating mutations other than the JAKs and STATs.8 Programmed cell death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) are important immune checkpoint molecules involved in immune evasion.9 PD-1/PD-L1 blockade by monoclonal antibodies has achieved great efficacy and is approved by the US Food and Drug Administration for a number of malignancies ZCYTOR7 such as gastric carcinoma,10 urothelial carcinoma,11 melanoma,12 and classical Hodgkin lymphoma (cHL).13 Recently, PD-1 blockade demonstrated a promising clinical response in patients with relapsed or refractory NKTL, and a strong PD-L1 expression level was found to correlate with better outcome.14,15 The genetic and molecular basis of PD-L1 overexpression has been investigated in multiple hematological malignancies.16-18 In cHL, copy gains of MG-262 9p24.1 locus resulted in PD-L1 overexpression,16 and in diffuse large B-cell lymphoma and adult T-cell lymphoma, the structural variants disrupting the 3 region of the gene led to aberrant transcripts with elevated expression.19 In ALK+ ALCL, the oncogenic fusion induced the expression of PD-L1 through STATWeb site. Cell lines and cell culture conditions are described in supplemental Methods. This study was approved by the SingHealth Centralized Institutional Review Board (study number 2004/407/F). Primary natural killer cell isolation for western blot Primary human natural killer (NK) cells were isolated from peripheral blood mononuclear cells by depletion of non-NK cells using a human NK cell isolation kit (Miltenyi Biotec). Purity of NK cells was evaluated by CD56-PE staining, and samples with more than 90% CD56+ cells were used. Cells were cultured in X-VIVO 15 medium (Lonza) supplemented with 5% human serum (Innova Biosciences) with 200 U/mL interleukin 2 (IL-2; Proleukin). Genomic DNA extraction Genomic DNA from formalin-fixed, paraffin-embedded, snap-frozen tumor tissues and whole blood was extracted as previously described.21 For buccal swab samples, DNA was extracted using EZNA Tissue DNA kit (Omega Bio-tek). Genomic DNA yield and quality were assessed as previously described.21 Deep-targeted capture sequencing Targeted capture sequencing was performed with a customized capture probe set that targeted exons of 188 JAK/STAT pathway-related genes (supplemental Table 2). One hundred seventy-one PTCL and NKTL gDNA samples were sequenced on the HiSeq2000 platform (Illumina) to a mean depth of 726-fold (supplemental Table 3). GATK was used to call single-nucleotide substitutions and insertion/deletions (indels), and candidate variants were MG-262 annotated using wAnnovar. A subset of mutations was randomly selected and verified by Sanger sequencing, as described previously,5.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed